This observational, descriptive registry (RACOVIR) examined how patients with non‑valvular atrial fibrillation (NVAF) treated with oral anticoagulants are managed in routine primary care practice in Spain. The primary aim was to describe patient profiles, treatment duration, anticoagulation control among VKA users, patient‑reported treatment satisfaction, and incidence rates of key clinical events by anticoagulant type.
RACOVIR included patients managed in primary care who had been receiving oral anticoagulants for at least six months before enrolment. The total cohort comprised 1,901 patients: 428 receiving vitamin K antagonists (VKAs) and 1,473 receiving direct oral anticoagulants (DOACs). No additional eligibility criteria or recruitment details beyond primary care management and minimum treatment duration were reported in the source abstract.
Functional autonomy and treatment satisfaction were assessed using the Barthel index and the ACTS (Anti‑Clot Treatment Scale) questionnaire, respectively. Anticoagulation control for patients on VKAs was evaluated by both a direct method and the Rosendaal method. Clinical event incidence rates were calculated per 1,000 person‑years and are reported with 95% confidence intervals in the abstract.
Among the registered patients, those treated with VKAs were reported to be significantly older and to have a higher prevalence of hypertension compared with those receiving DOACs. Mean duration of anticoagulant treatment differed by group: VKA‑treated patients had a mean treatment duration of 7.6 years, while DOAC‑treated patients had a mean duration of 3.8 years. The abstract attributes outcome differences partly to these variations in baseline profiles and treatment duration.
Anticoagulation control in the VKA cohort was reported using two established approaches. According to the direct method, 56.2% of VKA users achieved good anticoagulation control. Using the Rosendaal method, 59.0% achieved good control. No further breakdown of time in therapeutic range or subgroup analyses were reported in the abstract.
Patients receiving DOACs reported greater satisfaction across several domains as measured by the ACTS questionnaire. Reported advantages for the DOAC group included perceived treatment benefits, lower impact on daily life, and a more positive overall treatment effect compared with the VKA group. Specific ACTS domain scores or numerical values were not provided in the abstract.
Event incidence rates reported per 1,000 person‑years were higher in the DOAC group than in the VKA group for several endpoints. The abstract provides the following incidence rates (DOACs) with 95% confidence intervals:
The abstract states these rates were higher with DOACs than with VKAs; the VKA group rates and absolute counts were not included in the abstract text provided.
In this primary care registry from Spain, patient characteristics and treatment durations differed between those prescribed VKAs and DOACs. A majority of VKA users achieved good anticoagulation control by both direct and Rosendaal methods, while patients on DOACs reported higher treatment satisfaction. Despite greater reported satisfaction with DOACs, incidence rates for stroke, ischemic stroke, acute myocardial infarction, and major bleeding were reported as higher with DOACs than with VKAs in this cohort. The authors suggest that differences in baseline patient profiles and duration of therapy may partly explain the observed outcome differences.
The source is a preprint and has not been peer reviewed; the abstract cautions that findings should not be used to guide clinical practice without further evaluation.
The authors report that the study received ethical approval from the Ethics Committee for Research with Medicines of Hospital Clínico San Carlos (meeting held on May 12, 2021). They declared no competing interests. The authors state that all relevant patient consent procedures were followed. The dataset supporting the registry results is available at the SEMERGEN RACOVIR repository (link provided in the abstract). Specifics about trial registration identifiers or more detailed methodology beyond what is summarized in the abstract were not reported in the source text.